Bulletin
Investor Alert

New York Markets Open in:

Jan. 22, 2021, 8:16 a.m. EST

Cannabis Has Found A Huge New Growth Market For 2021

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Juva Life Inc. (JUVA)
  • X
    Juva Life Inc. (JUVAF)
  • X
    Aurora Cannabis Inc. (ACB)

or Cancel Already have a watchlist? Log In

Jan 22, 2021 (Baystreet.ca via COMTEX) -- In the biggest boost for cannabis since Canada legalized recreational use in 2018, the United Nations has reclassified marijuana, removing it from its most strict drug control list, paving the way for a flurry of positive legal activity the world over …

But while U.S. states line up to legalize recreational use, and while a change of power at the White House bodes well for cannabis stocks, there are two multi-billion-dollar elements that were missing, and one upstart company is aimed directly at this kingdom.

The kingdom is quality cannabis underpinned by the kind of big data that could make Big Pharma come knocking on doors.

And one of the potential keys to that kingdom could be held by Juva Life /zigman2/quotes/222626576/delayed CA:JUVA -3.61% /zigman2/quotes/222111944/composite JUVAF -3.82% , a California-based, vertically integrated company that is building an entire ecosystem of cannabis cultivation, R&D, distribution, retail, delivery and the missing data and IP links.

This could make all the difference, and the timing is perfect ...

Five more states just legalized marijuana in ballot initiatives on November 3rd, and stock prices are already heralding the Cannabis Boom 2.0.

The first round was a massive spend by deep-pocketed cannabis companies on building quantity with little regard for quality … and investors failed to see sustained returns.

The second round is about data-driven innovation, and that means quality.

And none of it means anything if Big Data isn’t there to prove it up and sell it on.

In a rapidly evolved marketplace, it’s Juva Life’s “precision cannabis” that aims to put the money-making science back into marijuana.

Part cannabis stock... part thera-tech stock... any of their 3 businesses could potentially reward investors with front-page news in 2021.

Here are 3 reasons to keep a very close eye on Juva Life Inc this quarter:

#1 The Second Cannabis Boom Starts in California

Investors in the first cannabis boom in 2018 who timed things right saw huge returns …

- Aurora Cannabis Inc. /zigman2/quotes/210559470/composite ACB -2.77% went from $4.43 on November 4th to $11.21 on November 9th.

- Canopy Growth /zigman2/quotes/200603886/composite CGC -1.39% shot from $19 on November 4th to almost $25 five days later, in a run it hasn’t seen since the first cannabis boom of 2018.

- Tilray /zigman2/quotes/209129655/composite TLRY -0.57% surged from $6.00 on November 4th to over $10 on November 9th.

But the first boom ended with a dull thud after a while because everyone focused on quantity rather than quality--and there wasn’t enough science.

Now, the legal marijuana market is on track to reach $73.6 billion by 2027, according to Grand View Research.

And California--where Juva is based--is one of the harbingers of the second boom--the better boom … the bigger and sustainable boom.

California's cannabis market is forecast to grow to $3.5 billion in 2021...

That’s even bigger than Canada’s market, and it’s a market that Juva Life /zigman2/quotes/222626576/delayed CA:JUVA -3.61% /zigman2/quotes/222111944/composite JUVAF -3.82% plans to dominate by playing the game in an entirely different way …

There’s probably only one guarantee for success in the cannabis sector: patents, permits and licenses.

And that’s exactly where Juva has the serious advantage. Its CEO received the first-ever permit in the state of California and Juva now has a head start on the competition.

But while they are on an aggressive expansion wave across California, they’re also aiming to make a significant footprint in a national medical cannabis market that is heading to $9 billion.

#2 The Biggest Money in Pot Is in Patents and IP

The real money in Cannabis 2.0 is probably in the patents … and Juva’s endgame is a focus on therapies, bolstered by growing retail sales revenues.

Juva’s flagship Hayward facility is already permitted and under construction. It’s a massive 18,000 sq ft structure with an adjoining 11,000 sq ft greenhouse.

And it’s ISO Class 5 cleanroom will be the scene of Juva’s state-of-the-art “science of cannabis” research and development.

They will do everything in this facility from cultivation and research to manufacturing and retail--all focused on achieving low-cost, high-quality growth operations combined with state-of-the-art research.

On October 22nd, Juva received a Conditional Use Permit, which is likely to expedite additional permitting, with full production anticipated by mid-2021.

It’s also just won conditional approval to develop a boutique flagship retail operation in a designer-styled environment at its Hayward facility by the city of Hayward.

Now comes the major push for development of “precision cannabis” products for targeted delivery of the “right formulation to the right individual at the right time”.

Juva Life /zigman2/quotes/222626576/delayed CA:JUVA -3.61% /zigman2/quotes/222111944/composite JUVAF -3.82% is going after the IP scene full force across multiple verticals, setting it up to be the “Integrated Vertical First Mover of Cannabis”, starting in California.

#3 This Is A Big Data Coup

Cannabis data is the difference between a successful market and a very successful market.

It’s the only thing connecting medical cannabis to medical science …

It’s the missing element that could cut millions of dollars off the costs of getting new cannabis based pharmaceutical drugs approved …

That also means it’s one thing that will attract the lucrative attention of Big Pharma.

/zigman2/quotes/222626576/delayed
CA : Canadian Securities Exchange
$ 1.60
-0.06 -3.61%
Volume: 502,818
Feb. 26, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$201.74 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/222111944/composite
US : U.S.: OTC
$ 1.26
-0.05 -3.82%
Volume: 678,362
Feb. 26, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$159.35 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210559470/composite
US : U.S.: NYSE
$ 10.52
-0.30 -2.77%
Volume: 11.88M
Feb. 26, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.10 billion
Rev. per Employee
$76,070
loading...
/zigman2/quotes/200603886/composite
US : U.S.: Nasdaq
$ 32.75
-0.46 -1.39%
Volume: 3.99M
Feb. 26, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$12.47 billion
Rev. per Employee
$67,581
loading...
/zigman2/quotes/209129655/composite
US : U.S.: Nasdaq
$ 24.36
-0.14 -0.57%
Volume: 19.37M
Feb. 26, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.18 billion
Rev. per Employee
$204,351
loading...
/zigman2/quotes/222626576/delayed
CA : Canadian Securities Exchange
$ 1.60
-0.06 -3.61%
Volume: 502,818
Feb. 26, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$201.74 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/222111944/composite
US : U.S.: OTC
$ 1.26
-0.05 -3.82%
Volume: 678,362
Feb. 26, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$159.35 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/222626576/delayed
CA : Canadian Securities Exchange
$ 1.60
-0.06 -3.61%
Volume: 502,818
Feb. 26, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$201.74 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/222111944/composite
US : U.S.: OTC
$ 1.26
-0.05 -3.82%
Volume: 678,362
Feb. 26, 2021 3:59p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$159.35 million
Rev. per Employee
N/A
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.